- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | iSpecimen stock hits 52-week low at $2.75 amid market challenges | 1 | Investing.com | ||
| Fr | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| Fr | iSpecimen expands cancer biospecimen services for research | 3 | Investing.com | ||
| ISPECIMEN Aktie jetzt für 0€ handeln | |||||
| Fr | iSpecimen Inc.: iSpecimen Will Serve as a Preferred Provider of Cancer Biospecimens | 228 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 20, 2024) - iSpecimen Inc. (NASDAQ: ISPC), a leading online marketplace for human biospecimens, today announced its strategic initiatives for 2025... ► Artikel lesen | |
| 13.12. | iSpecimen Up on Positive Results From NDQ | 2 | Baystreet.ca | ||
| 13.12. | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | 616 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen | |
| 13.12. | iSpecimen Inc.: iSpecimen Reports Positive Results on Next Day Quote Program for Researchers and Providers | 226 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 13, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 12.12. | iSpecimen appoints Robert Lim as CEO | 1 | Seeking Alpha | ||
| 12.12. | iSpecimen Inc.: iSpecimen Appoints Robert Lim as CEO and Director | 376 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - December 12, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 12.12. | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.12. | iSpecimen-Aktie erreicht 52-Wochen-Tief bei 3,4 US-Dollar | 1 | Investing.com Deutsch | ||
| 11.12. | iSpecimen stock hits 52-week low at $3.4 amid market challenges | 1 | Investing.com | ||
| 12.11. | iSpecimen Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.11. | iSpecimen Inc.: iSpecimen Named Top Competitor in $4.4 Billion USD Market | 250 | Newsfile | Woburn, Massachusetts--(Newsfile Corp. - November 8, 2024) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens... ► Artikel lesen | |
| 07.11. | iSpecimen Inc: iSpecimen Releases Cancer Biospecimen Offering; Orders Anticipated of Over $9,500,000 Annually | 2 | GlobeNewswire (USA) | ||
| 07.11. | iSpecimen Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 31.10. | iSpecimen Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.10. | iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 30.10. | iSpecimen sets $5 million public stock offering at $3 per share | 2 | Investing.com | ||
| 30.10. | iSpecimen setzt öffentliches Aktienangebot von 5 Millionen US-Dollar zu 3 US-Dollar pro Aktie fest | 2 | Investing.com Deutsch |
Seite:
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | 0,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| ILLUMINA | 129,86 | +0,14 % | INDEX-MONITOR: Moderna fliegt aus Nasdaq 100 - Palantir darf rein | NEW YORK (dpa-AFX) - Der US-Pharmakonzern und Impfstoffhersteller Moderna muss noch vor Weihnachten aus dem technologielastigen US-Aktienindex Nasdaq 100 weichen. Das hatte der Börsenbetreiber Nasdaq... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 38,800 | -0,26 % | 1 big new Green Flag for CRISPR Therapeutics' Stock | ||
| INTELLIA THERAPEUTICS | 11,700 | +0,60 % | Cathie Wood's ARK buys Intellia, sells Tesla in latest stock trades | ||
| EDITAS MEDICINE | 1,198 | -1,48 % | Editas Medicine Aktie stürzt auf 52-Wochen-Tief von 1,27 US-Dollar | ||
| DEFENCE THERAPEUTICS | 0,402 | -0,99 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 130,60 | -0,80 % | Neurocrine Announces Commercial Launch Of Crenessity In US | WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), Friday announced the commercial launch of Crenessity in the U.S. for adult and pediatric patients with classic congenital adrenal... ► Artikel lesen | |
| BLUEBIRD BIO | 7,400 | +0,68 % | bluebird bio Announces 1-for-20 Reverse Stock Split | SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it will proceed with a 1-for-20 reverse stock split ("Reverse Stock... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 18,905 | -0,42 % | Arrowhead Pharmaceuticals CEO verkauft Aktien im Wert von 246.109 US-Dollar | ||
| GALAPAGOS NV | 25,780 | -0,62 % | Galapagos NV: Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma | Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity and an encouraging safety profile in all NHL subtypes studied.96%... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,950 | -1,65 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| CARDIFF ONCOLOGY | 3,880 | -0,77 % | Cardiff Oncology CFO James Levine erwirbt Aktien im Wert von 36.725 US-Dollar | ||
| TWIST BIOSCIENCE | 46,170 | -0,17 % | Twist Bioscience Aktie: Kooperationen sorgen für Schub! | Die Twist Bioscience Corporation verzeichnete am 7. Dezember 2024 eine bemerkenswerte Entwicklung an der Börse. Der Aktienkurs stieg um 3,86 Prozent auf 52,70 USD, was die positive Monatsentwicklung... ► Artikel lesen | |
| REPLIGEN | 139,25 | -0,50 % | Repligen Corporation (RGEN) Fell Along with Peers | ||
| RECURSION PHARMACEUTICALS | 6,995 | 0,00 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
ISPECIMEN INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ISPECIMEN INC finden Sie auf Wallstreet Online.
